vimarsana.com

Latest Breaking News On - Healthcare company profile get rating - Page 1 : vimarsana.com

Zacks Investment Research Upgrades Definitive Healthcare (NASDAQ:DH) to Hold

Definitive Healthcare (NASDAQ:DH – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Thursday, Zacks.com reports. According to Zacks, “Definitive Healthcare Corp. provides healthcare commercial intelligence. The company’s SaaS platform creates new paths in the healthcare market. Definitive […]

Definitive Healthcare Corp (NASDAQ:DH) Given Average Rating of Hold by Analysts

Shares of Definitive Healthcare Corp. (NASDAQ:DH – Get Rating) have been given a consensus recommendation of “Hold” by the fourteen ratings firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, six have given a hold recommendation and six have given a buy recommendation […]

Definitive Healthcare (NASDAQ:DH) Updates FY 2022 Earnings Guidance

Definitive Healthcare (NASDAQ:DH – Get Rating) updated its FY 2022 earnings guidance on Monday. The company provided earnings per share guidance of $0.22-$0.26 for the period, compared to the consensus earnings per share estimate of $0.24. The company issued revenue guidance of $220.50 million-$224.50 million, compared to the consensus revenue estimate of $220.48 million.Definitive Healthcare […]

Comparing Yext (NYSE:YEXT) & Change Healthcare (NASDAQ:CHNG)

Yext (NYSE:YEXT – Get Rating) and Change Healthcare (NASDAQ:CHNG – Get Rating) are both business services companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings and valuation. Analyst Ratings This is a breakdown of current ratings for […]

SVB Leerink Lowers HCA Healthcare (NYSE:HCA) Price Target to $273 00

HCA Healthcare (NYSE:HCA – Get Rating) had its price objective dropped by equities researchers at SVB Leerink from $304.00 to $273.00 in a note issued to investors on Monday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. SVB Leerink’s target price would indicate a potential upside of 29.61% from the stock’s […]

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.